Analysis of two human monoclonal antibodies against melanomaYEILDING, N. M; GERSTNER, C; KIRKWOOD, J. M et al.International journal of cancer. 1992, Vol 52, Num 6, pp 967-973, issn 0020-7136Article

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsKIMBALL, A. B; GORDON, K. B; FAKHARZADEH, S et al.British journal of dermatology (1951). 2012, Vol 166, Num 4, pp 861-872, issn 0007-0963, 12 p.Article

Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001-2002KIMBALL, A. B; ROBINSON, D; WU, Y et al.Dermatology (Basel). 2008, Vol 217, Num 1, pp 27-37, issn 1018-8665, 11 p.Article

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesREICH, K; LANGLEY, R. G; LEBWOHL, M et al.British journal of dermatology (1951). 2011, Vol 164, Num 4, pp 862-872, issn 0007-0963, 11 p.Article

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialLEBWOHL, M; PAPP, K; HAN, C et al.British journal of dermatology (1951). 2010, Vol 162, Num 1, pp 137-146, issn 0007-0963, 10 p.Article